Elevance Health Inc (ELV · NYSE)

ELV · MARKET VIEW

Market view · as of Aug 31, 2026

Revenue (TTM)
$201.11B
+1.4% YoY
Gross margin
26.0%
EPS (latest q)
$7.45
vs $6.18 est · beat
52-wk position
78.3%
-7.6% vs 52w high · +4.9% 1mo

Price (last ~year)

Elevance Health (ELV) reported Q2 2026 revenue of $50.47 billion and net income of $1.46 billion, reflecting a 1.4% year-over-year revenue increase against a 13.1% decline in earnings. The company has exceeded earnings estimates in each of the last four quarters and maintains $31.04 billion in total debt with a 3.7x debt-to-EBITDA ratio. Shares recently closed at $394.43 as the company proceeds with a federal claim regarding Medicare star rating bonus payments.

Valuation

Market cap
$85.54B
P/E
17.64
PEG
1.403
P/B
1.929
P/S
0.425
Beta
0.692
Analyst target
$449.1

Quality & returns

Gross margin
26.0%
Operating margin
4.6%
Profit margin
2.5%
ROE
11.1%
ROA
3.8%

Price movement

Last
$394.43
1-month
+4.9%
3-month
+1.2%
RSI (14)
47
vs SMA200
+11.0%
52-wk position
78.3% -7.6% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-06-30$50.47B$2.06B$1.46B$2.10B
2026-03-31$50.18B$2.66B$1.76B$2.77B
2025-12-31$49.75B$581.0M$547.0M$987.0M
2025-09-30$50.71B$1.76B$1.19B$2.14B

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)

Other snapshots